Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?
Roberto Russo(Ospedale Policlinico San Martino), Aurora Parodi(Ospedale Policlinico San Martino), Emanuele Cozzani(Ospedale Policlinico San Martino), Niccolò Capurro(Ospedale Policlinico San Martino)
Cited by 31
Related Papers
European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes
|Journal of the European Academy of Dermatology and Venereology|2017|261
Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis
|British Journal of Dermatology|2006|136
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
|Frontiers in Medicine|2023|55
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study
|Expert Opinion on Biological Therapy|2020|43
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)
|Dermatology Practical & Conceptual|2024|34